Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthor: Jordan Chussler. Posted: 1/14/2026. 
Article Highlights - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, new companies list, and a handful can offer meaningful short-term upside potential. Of course, IPOs also carry substantial downside risk. Still, even conservative investors should not automatically dismiss recently public companies — some may merit a place in long-term, buy-and-hold portfolios. REVEALED: America just unlocked a $500 trillion asset
Everyone's talking about AI stocks but almost no one is talking about what AI actually runs on.
Nickel. Copper. Cobalt. Manganese.
America just secured exclusive rights to the largest untapped supply on Earth.
One company is already in position and this could be one of the most important AI infrastructure plays heading into 2026. The name and ticker are available here now >>> One biotechnology company in the healthcare sector that just went public could be an example of that. Last Year's IPO Success Stories Last year demonstrated why IPOs shouldn't be overlooked by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its debut. Short-term speculators captured a roughly 359% gain within 30 days of listing, but those who remained invested are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the notion that IPOs are exclusively high-risk startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already has a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—best known for its packaged bacon—waited 89 years before its IPO. Since going public in January 2025 the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is aiming for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions such as cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with targeting molecules that seek out specific cells (for example, cancer cells) to deliver localized doses of radiation. This targeted approach helps minimize damage to healthy tissue compared with some conventional radiation therapies. Industry consultancy Grand View Research estimates the global nuclear medicine market was nearly $18 billion in 2024 and could reach almost $35 billion by 2030, implying a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the dominant regional player — an important point for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Biotechnology Wall Street expects biotech IPO activity to rebound in 2026 after sector listings slowed in 2025 following funding changes. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised one of the larger sums seen for recent biotech listings. With $318 million raised in the IPO, the company now has a market cap of about $3.34 billion. According to the company's prospectus, Aktis' executive team includes veterans of drug development, regulatory approval and commercialization, with management having participated in bringing 14 currently FDA-approved products to market. At a technical level, Aktis focuses on targeted alpha radiopharmaceuticals — a class of precision cancer therapies that use proprietary technology to attack solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting significant interest from Eli Lilly (NYSE: LLY), which anchored the IPO. Per Reuters, Eli Lilly purchased $100 million of AKTS shares. This investment builds on a partnership formed in 2024 to develop tumor-targeting radiopharmaceuticals, under which Aktis received $60 million in cash and an equity investment from Lilly, plus potential milestone payments that could exceed $1 billion. The significance of Lilly's backing is notable. Eli Lilly, with a market cap around $1.01 trillion, is the largest Big Pharma company by market value; its net income rose nearly 109% year-over-year from 2023 to 2024. Between its equity stake and the recent $100 million share purchase, the maker of Zepbound now has a sizable financial interest in Aktis' success.
| 
